Sorriso Pharmaceuticals

Disease-modifying antibodies (private)

Privately held: no public share price · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1
TNF-alpha · IL-23 p19Biologic (subtype unspecified)
Inflammatory Bowel Disease
Ulcerative Colitis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.